For many women, the first thing that comes to mind when they hear "hormone therapy" is breast cancer. Maybe a friend warned you. Maybe your mother was told to stop her HRT years ago. Maybe a doctor simply said, "We don't really prescribe that anymore."
That fear is understandable, and it deserves a clear, honest answer. Here's where it came from, what the research has shown since, and how to think about HRT for yourself.
Where the fear came from
In 2002, the Women's Health Initiative (WHI), a large US study of hormone therapy, stopped one of its trials early. Early results suggested that women taking a combined estrogen and progestin pill had a higher risk of breast cancer and heart problems.
The news made headlines around the world. Almost overnight, millions of women stopped HRT, and many doctors stopped prescribing it. Two decades later, that fear is still with many women and many doctors.
What the headlines left out:
The average woman in the WHI was 63 years old, often more than ten years past menopause, which is not the group who usually starts HRT for symptoms.
The trial used one specific older combination: oral estrogens from horse urine plus a synthetic progestin.
The increase in risk was small in absolute terms, as the numbers below show.
What 20 years of follow-up showed
Researchers have continued to follow the women in the WHI for about two decades. The longer-term results, published in JAMA in 2020, showed:
Women who took estrogen alone (women without a uterus) had a lower rate of breast cancer than women on placebo.
Women who took the combined estrogen and progestin pill had a higher rate of breast cancer than women on placebo.
An earlier long-term analysis, also in JAMA, found that taking HRT for 5 to 7 years was not linked to a higher risk of dying from any cause over 18 years of follow-up.
Today, The Menopause Society's position is that for most healthy women under 60, or within 10 years of their last period, the benefits of HRT for symptoms and bone health outweigh the risks.
Putting the risk in perspective: per 1,000 women
Women's Health Concern, the patient arm of the British Menopause Society, compared different risk factors side by side. Among 1,000 women aged 50 to 59 in the UK, about 23 are expected to be diagnosed with breast cancer over the next 5 years. Compared with that:
Combined HRT: about 4 additional cases
Estrogen-only HRT: about 4 fewer cases
Drinking 2 or more units of alcohol a day: about 5 additional cases
Being overweight or obese (BMI 30 or more): about 24 additional cases
Smoking: about 3 additional cases
At least 2.5 hours of moderate exercise a week: about 7 fewer cases
In other words, for most women the extra risk from combined HRT is similar to that from drinking a couple of glasses of wine a day, and much smaller than the effect of body composition. And regular exercise lowers risk by more than combined HRT raises it.
Body-identical vs synthetic HRT
HRT today is often different from the pills used in the WHI. Many menopause specialists now prefer:
Estradiol through the skin (a patch, gel or spray). It is chemically identical to the estrogen your ovaries make, and taken this way it does not raise the risk of blood clots the way oral estrogen can.
Micronized progesterone, identical to your body's own progesterone, for women who still have a uterus.
The British Menopause Society notes that observational studies suggest micronized progesterone may carry a lower breast cancer risk than older synthetic progestogens, though more research is needed. And low-dose vaginal estrogen, used for dryness and urinary symptoms, is absorbed in very small amounts and is not associated with an increased breast cancer risk.
The type of HRT, the dose, how it's taken and how long you take it all matter. That's a conversation for a doctor who knows menopause, not a headline.
Who should talk to a doctor first
HRT isn't right for everyone. A careful discussion is especially important if you have:
a personal history of breast cancer, or another hormone-sensitive cancer
a BRCA gene variant, or a strong family history of breast or ovarian cancer
a history of blood clots, stroke or heart disease
liver disease
unexplained vaginal bleeding
Even then, there are often options, including non-hormonal treatments. Your doctor will look at your history and help you weigh the benefits and risks for you.
And whatever you decide about HRT, keep up your breast checks: monthly self-checks (SADARI), clinical breast exams (SADANIS), and mammograms on the schedule your doctor recommends.
Frequently asked questions
Does HRT cause breast cancer?
Combined HRT is linked to a small increase in breast cancer risk, which depends on the type and how long you take it. Estrogen-only HRT has not been shown to increase risk, and in the WHI it was linked to a lower rate.
Is there a "safe" time to start HRT?
For most healthy women, the benefits are greatest and the risks lowest when HRT is started before 60 or within 10 years of menopause.
How long can I take HRT?
There's no fixed cut-off for everyone. Many women take it for several years. Your doctor should review it with you at least once a year.
Is "natural" or "bioidentical" HRT from a compounding pharmacy safer?
Not necessarily. Regulated body-identical products (such as estradiol patches or gels and micronized progesterone) are tested for dose and quality. Custom-compounded hormones are not tested in the same way.
The takeaway
The fear around HRT and breast cancer came from a real study, but the headlines didn't tell the full story. For many women in their 40s and 50s, HRT is a safe and effective option, and for some, it also protects long-term health. The right answer depends on you: your symptoms, your history and your preferences.
Have questions about HRT and your own risk? In a Magnolia Hormone & Health Consultation, a Magnolia Navigator Coach™ helps you organize your symptoms and family history, and a menopause-trained Magnolia doctor talks you through your options, including whether HRT is right for you. Book your consultation here.
Sources
Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA.
Chlebowski R.T. et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA.
Manson J.E. et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA.
The Menopause Society (2022). The 2022 hormone therapy position statement. Menopause.
Women's Health Concern / British Menopause Society. Understanding the risks of breast cancer.
British Menopause Society (2023). Hormone replacement therapy and breast cancer risk.
This article is for education only and is not a substitute for medical advice. Please talk to your doctor before starting or stopping any treatment.
